research use only

Angiotensin (1-7) RAAS inhibitor

Cat.No.S9820

Angiotensin (1-7) (Ang-(1-7), Angiotensin fragment 1-7) is a bioactive component of the renin-angiotensin system that is formed endogenously from either Ang I or Ang II. This compound is a canine ACE inhibitor with an IC50 of 0.65 μM and inhibits the activity mediated by myostatin through Mas receptor.
Angiotensin (1-7) RAAS inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 899.00

Quality Control

Batch: S982001 Water]50 mg/mL]false]DMSO]Insoluble]false]Ethanol]Insoluble]false Purity: 99.30%
99.30

Chemical Information, Storage & Stability

Molecular Weight 899.00 Formula

C41H62N12O11

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 51833-78-4 -- Storage of Stock Solutions

Synonyms Ang-(1-7), Angiotensin fragment 1-7 Smiles CCC(C)C(NC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(NC(=O)C(CCCN=C(N)N)NC(=O)C(N)CC(O)=O)C(C)C)C(=O)NC(CC2=CN=C[NH]2)C(=O)N3CCCC3C(O)=O

Solubility

In vitro
Batch:

Water : 50 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
Mas receptor [1]
ACE [1]
0.65 μM
In vitro

This compound prevents the decrease of the myotube diameter and MHC Levels Induced by myostatin in C2C12 cells. Angiotensin (1-7) decreases the myostatin-dependent increment of E3 ubiquitin ligases and ROS, the NF-κB signaling induced by myostatin, the myostatin-dependent activity through the mas receptor and Akt/PKB activity in C2C12 myotubes.[1]

In vivo

Daily administration of Angiotensin (1-7) significantly reduces colitis severity observable at both gross and histological levels in DSS treated mice. The anti-inflammatory effects of this compound treatment are associated with a reduction in the phosphorylated forms of p38 MAPK, ERK1/2 and Akt post DSS induction, and its anti-inflammatory properties are in part mediated through reduction of Ang II levels.[3]

References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06282965 Not yet recruiting
Traumatic Brain Injury
University of Arizona|United States Department of Defense
March 2024 Phase 1|Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map